American	B:C3495436
cutaneous	I:C3495436
leishmaniasis	I:C3495436
:	O

In	O
situ	O
immune	B:C0301872
response	I:C0301872
of	O
patients	O
with	O
recent	O
and	O
late	O
lesions	O
TNF-α	O
,	O
IFN-γ	O
,	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
CD68	O
and	O
CD57	O
were	O
evaluated	O
in	O
biopsies	O
of	O
patients	O
with	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
living	O
in	O
Sorocaba	O
,	O
Brazil	O
.	O

In	O
situ	O
immune	O
response	I:C0301872
of	O
patients	O
with	O
recent	B:C0332665
and	O
late	O
lesions	O
TNF-α	O
,	O
IFN-γ	O
,	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
CD68	O
and	O
CD57	O
were	O
evaluated	O
in	O
biopsies	O
of	O
patients	O
with	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
living	O
in	O
Sorocaba	O
,	O
Brazil	O
.	O

In	O
situ	O
immune	O
response	I:C0301872
of	O
patients	O
with	O
recent	O
and	O
late	O
lesions	B:C0221198
TNF-α	O
,	O
IFN-γ	O
,	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
CD68	O
and	O
CD57	O
were	O
evaluated	O
in	O
biopsies	O
of	O
patients	O
with	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
living	O
in	O
Sorocaba	O
,	O
Brazil	O
.	O

In	O
situ	O
immune	O
response	I:C0301872
of	O
patients	O
with	O
recent	O
and	O
late	O
lesions	O
TNF-α	B:C1456820
,	O
IFN-γ	O
,	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
CD68	O
and	O
CD57	O
were	O
evaluated	O
in	O
biopsies	O
of	O
patients	O
with	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
living	O
in	O
Sorocaba	O
,	O
Brazil	O
.	O

In	O
situ	O
immune	O
response	I:C0301872
of	O
patients	O
with	O
recent	O
and	O
late	O
lesions	O
TNF-α	O
,	O
IFN-γ	B:C0021745
,	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
CD68	O
and	O
CD57	O
were	O
evaluated	O
in	O
biopsies	O
of	O
patients	O
with	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
living	O
in	O
Sorocaba	O
,	O
Brazil	O
.	O

In	O
situ	O
immune	O
response	I:C0301872
of	O
patients	O
with	O
recent	O
and	O
late	O
lesions	O
TNF-α	O
,	O
IFN-γ	O
,	O
IL	B:C0085295
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
CD68	O
and	O
CD57	O
were	O
evaluated	O
in	O
biopsies	O
of	O
patients	O
with	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
living	O
in	O
Sorocaba	O
,	O
Brazil	O
.	O

In	O
situ	O
immune	O
response	I:C0301872
of	O
patients	O
with	O
recent	O
and	O
late	O
lesions	O
TNF-α	O
,	O
IFN-γ	O
,	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
IL	B:C0384648
-	I:C0384648
17	I:C0384648
,	O
CD68	O
and	O
CD57	O
were	O
evaluated	O
in	O
biopsies	O
of	O
patients	O
with	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
living	O
in	O
Sorocaba	O
,	O
Brazil	O
.	O

In	O
situ	O
immune	O
response	I:C0301872
of	O
patients	O
with	O
recent	O
and	O
late	O
lesions	O
TNF-α	O
,	O
IFN-γ	O
,	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
CD68	B:C0108799
and	O
CD57	O
were	O
evaluated	O
in	O
biopsies	O
of	O
patients	O
with	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
living	O
in	O
Sorocaba	O
,	O
Brazil	O
.	O

In	O
situ	O
immune	O
response	I:C0301872
of	O
patients	O
with	O
recent	O
and	O
late	O
lesions	O
TNF-α	O
,	O
IFN-γ	O
,	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
CD68	O
and	O
CD57	B:C0054965
were	O
evaluated	O
in	O
biopsies	O
of	O
patients	O
with	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
living	O
in	O
Sorocaba	O
,	O
Brazil	O
.	O

In	O
situ	O
immune	O
response	I:C0301872
of	O
patients	O
with	O
recent	O
and	O
late	O
lesions	O
TNF-α	O
,	O
IFN-γ	O
,	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
CD68	O
and	O
CD57	O
were	O
evaluated	B:C0220825
in	O
biopsies	O
of	O
patients	O
with	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
living	O
in	O
Sorocaba	O
,	O
Brazil	O
.	O

In	O
situ	O
immune	O
response	I:C0301872
of	O
patients	O
with	O
recent	O
and	O
late	O
lesions	O
TNF-α	O
,	O
IFN-γ	O
,	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
CD68	O
and	O
CD57	O
were	O
evaluated	O
in	O
biopsies	B:C0005558
of	O
patients	O
with	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
living	O
in	O
Sorocaba	O
,	O
Brazil	O
.	O

In	O
situ	O
immune	O
response	I:C0301872
of	O
patients	O
with	O
recent	O
and	O
late	O
lesions	O
TNF-α	O
,	O
IFN-γ	O
,	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
CD68	O
and	O
CD57	O
were	O
evaluated	O
in	O
biopsies	O
of	O
patients	O
with	O
American	B:C3495436
cutaneous	I:C3495436
leishmaniasis	I:C3495436
living	O
in	O
Sorocaba	O
,	O
Brazil	O
.	O

In	O
situ	O
immune	O
response	I:C0301872
of	O
patients	O
with	O
recent	O
and	O
late	O
lesions	O
TNF-α	O
,	O
IFN-γ	O
,	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
CD68	O
and	O
CD57	O
were	O
evaluated	O
in	O
biopsies	O
of	O
patients	O
with	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
living	O
in	O
Sorocaba	B:C0017446
,	O
Brazil	O
.	O

In	O
situ	O
immune	O
response	I:C0301872
of	O
patients	O
with	O
recent	O
and	O
late	O
lesions	O
TNF-α	O
,	O
IFN-γ	O
,	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
CD68	O
and	O
CD57	O
were	O
evaluated	O
in	O
biopsies	O
of	O
patients	O
with	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
living	O
in	O
Sorocaba	O
,	O
Brazil	B:C0006137
.	O

The	O
analyses	B:C0936012
were	O
performed	O
considering	O
the	O
time	O
of	O
lesions	O
from	O
23	O
patients	O
with	O
recent	O
lesions	I:C0332665
(	O
Group	O
I	I:C1257890
)	O
and	O
19	O
patients	O
with	O
late	O
lesions	O
(	O
Group	O
II	I:C1257890
)	O
.	O

The	O
analyses	O
were	O
performed	O
considering	O
the	O
time	O
of	O
lesions	B:C0221198
from	O
23	O
patients	O
with	O
recent	O
lesions	I:C0332665
(	O
Group	O
I	I:C1257890
)	O
and	O
19	O
patients	O
with	O
late	O
lesions	O
(	O
Group	O
II	I:C1257890
)	O
.	O

The	O
analyses	O
were	O
performed	O
considering	O
the	O
time	O
of	O
lesions	O
from	O
23	O
patients	O
with	O
recent	B:C0332665
lesions	I:C0332665
(	O
Group	O
I	I:C1257890
)	O
and	O
19	O
patients	O
with	O
late	O
lesions	O
(	O
Group	O
II	I:C1257890
)	O
.	O

The	O
analyses	O
were	O
performed	O
considering	O
the	O
time	O
of	O
lesions	O
from	O
23	O
patients	O
with	O
recent	O
lesions	I:C0332665
(	O
Group	B:C1257890
I	I:C1257890
)	O
and	O
19	O
patients	O
with	O
late	O
lesions	O
(	O
Group	O
II	I:C1257890
)	O
.	O

The	O
analyses	O
were	O
performed	O
considering	O
the	O
time	O
of	O
lesions	O
from	O
23	O
patients	O
with	O
recent	O
lesions	I:C0332665
(	O
Group	O
I	I:C1257890
)	O
and	O
19	O
patients	O
with	O
late	O
lesions	B:C0221198
(	O
Group	O
II	I:C1257890
)	O
.	O

The	O
analyses	O
were	O
performed	O
considering	O
the	O
time	O
of	O
lesions	O
from	O
23	O
patients	O
with	O
recent	O
lesions	I:C0332665
(	O
Group	O
I	I:C1257890
)	O
and	O
19	O
patients	O
with	O
late	O
lesions	O
(	O
Group	B:C1257890
II	I:C1257890
)	O
.	O

All	O
patients	O
were	O
infected	B:C0439663
with	O
Leishmania	O
(	I:C0023271
Viannia	I:C0023271
)	I:C0023271
braziliensis	I:C0023271
.	O

All	O
patients	O
were	O
infected	O
with	O
Leishmania	B:C0023271
(	I:C0023271
Viannia	I:C0023271
)	I:C0023271
braziliensis	I:C0023271
.	O

Immunostaining	B:C0022885
cells	O
for	O
CD68	O
,	O
CD57	O
,	O
TNF	O
-	I:C1456820
α	I:C1456820
,	O
IFN	O
-γ	I:C0021745
,	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
IL	O
-	I:C0384648
17	I:C0384648
were	O
performed	O
by	O
immunohistochemistry	O
.	O

Immunostaining	O
cells	B:C0007634
for	O
CD68	O
,	O
CD57	O
,	O
TNF	O
-	I:C1456820
α	I:C1456820
,	O
IFN	O
-γ	I:C0021745
,	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
IL	O
-	I:C0384648
17	I:C0384648
were	O
performed	O
by	O
immunohistochemistry	O
.	O

Immunostaining	O
cells	O
for	O
CD68	B:C0108799
,	O
CD57	O
,	O
TNF	O
-	I:C1456820
α	I:C1456820
,	O
IFN	O
-γ	I:C0021745
,	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
IL	O
-	I:C0384648
17	I:C0384648
were	O
performed	O
by	O
immunohistochemistry	O
.	O

Immunostaining	O
cells	O
for	O
CD68	O
,	O
CD57	B:C0054965
,	O
TNF	O
-	I:C1456820
α	I:C1456820
,	O
IFN	O
-γ	I:C0021745
,	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
IL	O
-	I:C0384648
17	I:C0384648
were	O
performed	O
by	O
immunohistochemistry	O
.	O

Immunostaining	O
cells	O
for	O
CD68	O
,	O
CD57	O
,	O
TNF	B:C1456820
-	I:C1456820
α	I:C1456820
,	O
IFN	O
-γ	I:C0021745
,	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
IL	O
-	I:C0384648
17	I:C0384648
were	O
performed	O
by	O
immunohistochemistry	O
.	O

Immunostaining	O
cells	O
for	O
CD68	O
,	O
CD57	O
,	O
TNF	O
-	I:C1456820
α	I:C1456820
,	O
IFN	B:C0021745
-γ	I:C0021745
,	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
IL	O
-	I:C0384648
17	I:C0384648
were	O
performed	O
by	O
immunohistochemistry	O
.	O

Immunostaining	O
cells	O
for	O
CD68	O
,	O
CD57	O
,	O
TNF	O
-	I:C1456820
α	I:C1456820
,	O
IFN	O
-γ	I:C0021745
,	O
IL	B:C0085295
-	I:C0085295
10	I:C0085295
and	O
IL	O
-	I:C0384648
17	I:C0384648
were	O
performed	O
by	O
immunohistochemistry	O
.	O

Immunostaining	O
cells	O
for	O
CD68	O
,	O
CD57	O
,	O
TNF	O
-	I:C1456820
α	I:C1456820
,	O
IFN	O
-γ	I:C0021745
,	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
IL	B:C0384648
-	I:C0384648
17	I:C0384648
were	O
performed	O
by	O
immunohistochemistry	O
.	O

Immunostaining	O
cells	O
for	O
CD68	O
,	O
CD57	O
,	O
TNF	O
-	I:C1456820
α	I:C1456820
,	O
IFN	O
-γ	I:C0021745
,	O
IL	O
-	I:C0085295
10	I:C0085295
and	O
IL	O
-	I:C0384648
17	I:C0384648
were	O
performed	O
by	O
immunohistochemistry	B:C0021044
.	O

Except	O
for	O
CD68	B:C0108799
and	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
the	O
distribution	O
of	O
in	O
situ	O
for	O
CD57	O
,	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
TNF-α	O
and	O
IFN	O
-γ	I:C0021745
showed	O
that	O
patients	O
with	O
recent	O
lesions	I:C0332665
expressed	O
higher	O
levels	O
than	O
those	O
with	O
late	O
lesions	O
.	O

Except	O
for	O
CD68	O
and	O
IL	B:C0384648
-	I:C0384648
17	I:C0384648
,	O
the	O
distribution	O
of	O
in	O
situ	O
for	O
CD57	O
,	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
TNF-α	O
and	O
IFN	O
-γ	I:C0021745
showed	O
that	O
patients	O
with	O
recent	O
lesions	I:C0332665
expressed	O
higher	O
levels	O
than	O
those	O
with	O
late	O
lesions	O
.	O

Except	O
for	O
CD68	O
and	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
the	O
distribution	O
of	O
in	O
situ	O
for	O
CD57	B:C0054965
,	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
TNF-α	O
and	O
IFN	O
-γ	I:C0021745
showed	O
that	O
patients	O
with	O
recent	O
lesions	I:C0332665
expressed	O
higher	O
levels	O
than	O
those	O
with	O
late	O
lesions	O
.	O

Except	O
for	O
CD68	O
and	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
the	O
distribution	O
of	O
in	O
situ	O
for	O
CD57	O
,	O
IL	B:C0085295
-	I:C0085295
10	I:C0085295
,	O
TNF-α	O
and	O
IFN	O
-γ	I:C0021745
showed	O
that	O
patients	O
with	O
recent	O
lesions	I:C0332665
expressed	O
higher	O
levels	O
than	O
those	O
with	O
late	O
lesions	O
.	O

Except	O
for	O
CD68	O
and	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
the	O
distribution	O
of	O
in	O
situ	O
for	O
CD57	O
,	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
TNF-α	B:C1456820
and	O
IFN	O
-γ	I:C0021745
showed	O
that	O
patients	O
with	O
recent	O
lesions	I:C0332665
expressed	O
higher	O
levels	O
than	O
those	O
with	O
late	O
lesions	O
.	O

Except	O
for	O
CD68	O
and	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
the	O
distribution	O
of	O
in	O
situ	O
for	O
CD57	O
,	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
TNF-α	O
and	O
IFN	B:C0021745
-γ	I:C0021745
showed	O
that	O
patients	O
with	O
recent	O
lesions	I:C0332665
expressed	O
higher	O
levels	O
than	O
those	O
with	O
late	O
lesions	O
.	O

Except	O
for	O
CD68	O
and	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
the	O
distribution	O
of	O
in	O
situ	O
for	O
CD57	O
,	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
TNF-α	O
and	O
IFN	O
-γ	I:C0021745
showed	O
that	O
patients	O
with	O
recent	B:C0332665
lesions	I:C0332665
expressed	O
higher	O
levels	O
than	O
those	O
with	O
late	O
lesions	O
.	O

Except	O
for	O
CD68	O
and	O
IL	O
-	I:C0384648
17	I:C0384648
,	O
the	O
distribution	O
of	O
in	O
situ	O
for	O
CD57	O
,	O
IL	O
-	I:C0085295
10	I:C0085295
,	O
TNF-α	O
and	O
IFN	O
-γ	I:C0021745
showed	O
that	O
patients	O
with	O
recent	O
lesions	I:C0332665
expressed	O
higher	O
levels	O
than	O
those	O
with	O
late	O
lesions	B:C0221198
.	O

The	O
comparison	O
of	O
cytokine	B:C0079189
expression	O
/	O
group	O
showed	O
that	O
IL	O
-	I:C0085295
10	I:C0085295
was	O
significantly	O
higher	O
than	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
IFN	O
-γ	I:C0021745
(	O
similar	O
data	O
were	O
shown	O
in	O
IL	O
-	I:C0384648
17	I:C0384648
compared	O
with	O
TNF	O
-α	I:C1456820
)	O
,	O
suggesting	O
an	O
immunological	O
balance	O
between	O
inflammatory	O
-	O
anti-inflammatory	O
agents	I:C0003209
.	O

The	O
comparison	O
of	O
cytokine	O
expression	B:C1171362
/	O
group	O
showed	O
that	O
IL	O
-	I:C0085295
10	I:C0085295
was	O
significantly	O
higher	O
than	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
IFN	O
-γ	I:C0021745
(	O
similar	O
data	O
were	O
shown	O
in	O
IL	O
-	I:C0384648
17	I:C0384648
compared	O
with	O
TNF	O
-α	I:C1456820
)	O
,	O
suggesting	O
an	O
immunological	O
balance	O
between	O
inflammatory	O
-	O
anti-inflammatory	O
agents	I:C0003209
.	O

The	O
comparison	O
of	O
cytokine	O
expression	O
/	O
group	O
showed	O
that	O
IL	B:C0085295
-	I:C0085295
10	I:C0085295
was	O
significantly	O
higher	O
than	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
IFN	O
-γ	I:C0021745
(	O
similar	O
data	O
were	O
shown	O
in	O
IL	O
-	I:C0384648
17	I:C0384648
compared	O
with	O
TNF	O
-α	I:C1456820
)	O
,	O
suggesting	O
an	O
immunological	O
balance	O
between	O
inflammatory	O
-	O
anti-inflammatory	O
agents	I:C0003209
.	O

The	O
comparison	O
of	O
cytokine	O
expression	O
/	O
group	O
showed	O
that	O
IL	O
-	I:C0085295
10	I:C0085295
was	O
significantly	O
higher	O
than	O
IL	B:C0384648
-	I:C0384648
17	I:C0384648
and	O
IFN	O
-γ	I:C0021745
(	O
similar	O
data	O
were	O
shown	O
in	O
IL	O
-	I:C0384648
17	I:C0384648
compared	O
with	O
TNF	O
-α	I:C1456820
)	O
,	O
suggesting	O
an	O
immunological	O
balance	O
between	O
inflammatory	O
-	O
anti-inflammatory	O
agents	I:C0003209
.	O

The	O
comparison	O
of	O
cytokine	O
expression	O
/	O
group	O
showed	O
that	O
IL	O
-	I:C0085295
10	I:C0085295
was	O
significantly	O
higher	O
than	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
IFN	B:C0021745
-γ	I:C0021745
(	O
similar	O
data	O
were	O
shown	O
in	O
IL	O
-	I:C0384648
17	I:C0384648
compared	O
with	O
TNF	O
-α	I:C1456820
)	O
,	O
suggesting	O
an	O
immunological	O
balance	O
between	O
inflammatory	O
-	O
anti-inflammatory	O
agents	I:C0003209
.	O

The	O
comparison	O
of	O
cytokine	O
expression	O
/	O
group	O
showed	O
that	O
IL	O
-	I:C0085295
10	I:C0085295
was	O
significantly	O
higher	O
than	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
IFN	O
-γ	I:C0021745
(	O
similar	O
data	O
were	O
shown	O
in	O
IL	B:C0384648
-	I:C0384648
17	I:C0384648
compared	O
with	O
TNF	O
-α	I:C1456820
)	O
,	O
suggesting	O
an	O
immunological	O
balance	O
between	O
inflammatory	O
-	O
anti-inflammatory	O
agents	I:C0003209
.	O

The	O
comparison	O
of	O
cytokine	O
expression	O
/	O
group	O
showed	O
that	O
IL	O
-	I:C0085295
10	I:C0085295
was	O
significantly	O
higher	O
than	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
IFN	O
-γ	I:C0021745
(	O
similar	O
data	O
were	O
shown	O
in	O
IL	O
-	I:C0384648
17	I:C0384648
compared	O
with	O
TNF	B:C1456820
-α	I:C1456820
)	O
,	O
suggesting	O
an	O
immunological	O
balance	O
between	O
inflammatory	O
-	O
anti-inflammatory	O
agents	I:C0003209
.	O

The	O
comparison	O
of	O
cytokine	O
expression	O
/	O
group	O
showed	O
that	O
IL	O
-	I:C0085295
10	I:C0085295
was	O
significantly	O
higher	O
than	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
IFN	O
-γ	I:C0021745
(	O
similar	O
data	O
were	O
shown	O
in	O
IL	O
-	I:C0384648
17	I:C0384648
compared	O
with	O
TNF	O
-α	I:C1456820
)	O
,	O
suggesting	O
an	O
immunological	O
balance	B:C0014653
between	O
inflammatory	O
-	O
anti-inflammatory	O
agents	I:C0003209
.	O

The	O
comparison	O
of	O
cytokine	O
expression	O
/	O
group	O
showed	O
that	O
IL	O
-	I:C0085295
10	I:C0085295
was	O
significantly	O
higher	O
than	O
IL	O
-	I:C0384648
17	I:C0384648
and	O
IFN	O
-γ	I:C0021745
(	O
similar	O
data	O
were	O
shown	O
in	O
IL	O
-	I:C0384648
17	I:C0384648
compared	O
with	O
TNF	O
-α	I:C1456820
)	O
,	O
suggesting	O
an	O
immunological	O
balance	O
between	O
inflammatory	O
-	O
anti-inflammatory	B:C0003209
agents	I:C0003209
.	O

This	O
balance	B:C0014653
was	O
similar	O
for	O
two	O
groups	O
of	O
patients	O
.	O

This	O
balance	O
was	O
similar	O
for	O
two	O
groups	B:C1257890
of	O
patients	O
.	O

In	O
conclusion	O
,	O
these	O
data	O
suggested	O
that	O
(	O
i	O
)	O
patients	O
from	O
Group	B:C1257890
I	I:C1257890
had	O
recent	O
lesions	I:C0332665
(	O
in	O
the	O
beginning	O
of	O
chronic	O
phase	O
)	O
compared	O
to	O
those	O
from	O
Group	O
II	I:C1257890
and	O
(	O
ii	O
)	O
the	O
modulation	O
of	O
inflammatory	O
response	I:C1155266
in	O
patients	O
with	O
recent	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
was	O
correlated	O
with	O
IL	O
-	I:C0085295
10	I:C0085295
expression	O
in	O
skin	O
lesions	I:C0037284
preventing	O
the	O
development	O
of	O
mucosal	O
forms	I:C0574771
.	O

In	O
conclusion	O
,	O
these	O
data	O
suggested	O
that	O
(	O
i	O
)	O
patients	O
from	O
Group	O
I	I:C1257890
had	O
recent	B:C0332665
lesions	I:C0332665
(	O
in	O
the	O
beginning	O
of	O
chronic	O
phase	O
)	O
compared	O
to	O
those	O
from	O
Group	O
II	I:C1257890
and	O
(	O
ii	O
)	O
the	O
modulation	O
of	O
inflammatory	O
response	I:C1155266
in	O
patients	O
with	O
recent	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
was	O
correlated	O
with	O
IL	O
-	I:C0085295
10	I:C0085295
expression	O
in	O
skin	O
lesions	I:C0037284
preventing	O
the	O
development	O
of	O
mucosal	O
forms	I:C0574771
.	O

In	O
conclusion	O
,	O
these	O
data	O
suggested	O
that	O
(	O
i	O
)	O
patients	O
from	O
Group	O
I	I:C1257890
had	O
recent	O
lesions	I:C0332665
(	O
in	O
the	O
beginning	O
of	O
chronic	O
phase	O
)	O
compared	O
to	O
those	O
from	O
Group	B:C1257890
II	I:C1257890
and	O
(	O
ii	O
)	O
the	O
modulation	O
of	O
inflammatory	O
response	I:C1155266
in	O
patients	O
with	O
recent	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
was	O
correlated	O
with	O
IL	O
-	I:C0085295
10	I:C0085295
expression	O
in	O
skin	O
lesions	I:C0037284
preventing	O
the	O
development	O
of	O
mucosal	O
forms	I:C0574771
.	O

In	O
conclusion	O
,	O
these	O
data	O
suggested	O
that	O
(	O
i	O
)	O
patients	O
from	O
Group	O
I	I:C1257890
had	O
recent	O
lesions	I:C0332665
(	O
in	O
the	O
beginning	O
of	O
chronic	O
phase	O
)	O
compared	O
to	O
those	O
from	O
Group	O
II	I:C1257890
and	O
(	O
ii	O
)	O
the	O
modulation	O
of	O
inflammatory	B:C1155266
response	I:C1155266
in	O
patients	O
with	O
recent	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
was	O
correlated	O
with	O
IL	O
-	I:C0085295
10	I:C0085295
expression	O
in	O
skin	O
lesions	I:C0037284
preventing	O
the	O
development	O
of	O
mucosal	O
forms	I:C0574771
.	O

In	O
conclusion	O
,	O
these	O
data	O
suggested	O
that	O
(	O
i	O
)	O
patients	O
from	O
Group	O
I	I:C1257890
had	O
recent	O
lesions	I:C0332665
(	O
in	O
the	O
beginning	O
of	O
chronic	O
phase	O
)	O
compared	O
to	O
those	O
from	O
Group	O
II	I:C1257890
and	O
(	O
ii	O
)	O
the	O
modulation	O
of	O
inflammatory	O
response	I:C1155266
in	O
patients	O
with	O
recent	O
American	B:C3495436
cutaneous	I:C3495436
leishmaniasis	I:C3495436
was	O
correlated	O
with	O
IL	O
-	I:C0085295
10	I:C0085295
expression	O
in	O
skin	O
lesions	I:C0037284
preventing	O
the	O
development	O
of	O
mucosal	O
forms	I:C0574771
.	O

In	O
conclusion	O
,	O
these	O
data	O
suggested	O
that	O
(	O
i	O
)	O
patients	O
from	O
Group	O
I	I:C1257890
had	O
recent	O
lesions	I:C0332665
(	O
in	O
the	O
beginning	O
of	O
chronic	O
phase	O
)	O
compared	O
to	O
those	O
from	O
Group	O
II	I:C1257890
and	O
(	O
ii	O
)	O
the	O
modulation	O
of	O
inflammatory	O
response	I:C1155266
in	O
patients	O
with	O
recent	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
was	O
correlated	O
with	O
IL	B:C0085295
-	I:C0085295
10	I:C0085295
expression	O
in	O
skin	O
lesions	I:C0037284
preventing	O
the	O
development	O
of	O
mucosal	O
forms	I:C0574771
.	O

In	O
conclusion	O
,	O
these	O
data	O
suggested	O
that	O
(	O
i	O
)	O
patients	O
from	O
Group	O
I	I:C1257890
had	O
recent	O
lesions	I:C0332665
(	O
in	O
the	O
beginning	O
of	O
chronic	O
phase	O
)	O
compared	O
to	O
those	O
from	O
Group	O
II	I:C1257890
and	O
(	O
ii	O
)	O
the	O
modulation	O
of	O
inflammatory	O
response	I:C1155266
in	O
patients	O
with	O
recent	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
was	O
correlated	O
with	O
IL	O
-	I:C0085295
10	I:C0085295
expression	B:C1171362
in	O
skin	O
lesions	I:C0037284
preventing	O
the	O
development	O
of	O
mucosal	O
forms	I:C0574771
.	O

In	O
conclusion	O
,	O
these	O
data	O
suggested	O
that	O
(	O
i	O
)	O
patients	O
from	O
Group	O
I	I:C1257890
had	O
recent	O
lesions	I:C0332665
(	O
in	O
the	O
beginning	O
of	O
chronic	O
phase	O
)	O
compared	O
to	O
those	O
from	O
Group	O
II	I:C1257890
and	O
(	O
ii	O
)	O
the	O
modulation	O
of	O
inflammatory	O
response	I:C1155266
in	O
patients	O
with	O
recent	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
was	O
correlated	O
with	O
IL	O
-	I:C0085295
10	I:C0085295
expression	O
in	O
skin	B:C0037284
lesions	I:C0037284
preventing	O
the	O
development	O
of	O
mucosal	O
forms	I:C0574771
.	O

In	O
conclusion	O
,	O
these	O
data	O
suggested	O
that	O
(	O
i	O
)	O
patients	O
from	O
Group	O
I	I:C1257890
had	O
recent	O
lesions	I:C0332665
(	O
in	O
the	O
beginning	O
of	O
chronic	O
phase	O
)	O
compared	O
to	O
those	O
from	O
Group	O
II	I:C1257890
and	O
(	O
ii	O
)	O
the	O
modulation	O
of	O
inflammatory	O
response	I:C1155266
in	O
patients	O
with	O
recent	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
was	O
correlated	O
with	O
IL	O
-	I:C0085295
10	I:C0085295
expression	O
in	O
skin	O
lesions	I:C0037284
preventing	O
the	O
development	B:C0243107
of	O
mucosal	O
forms	I:C0574771
.	O

In	O
conclusion	O
,	O
these	O
data	O
suggested	O
that	O
(	O
i	O
)	O
patients	O
from	O
Group	O
I	I:C1257890
had	O
recent	O
lesions	I:C0332665
(	O
in	O
the	O
beginning	O
of	O
chronic	O
phase	O
)	O
compared	O
to	O
those	O
from	O
Group	O
II	I:C1257890
and	O
(	O
ii	O
)	O
the	O
modulation	O
of	O
inflammatory	O
response	I:C1155266
in	O
patients	O
with	O
recent	O
American	O
cutaneous	I:C3495436
leishmaniasis	I:C3495436
was	O
correlated	O
with	O
IL	O
-	I:C0085295
10	I:C0085295
expression	O
in	O
skin	O
lesions	I:C0037284
preventing	O
the	O
development	O
of	O
mucosal	B:C0574771
forms	I:C0574771
.	O

The	O
parasite	B:C0030498
treatment	O
also	O
prevented	O
the	O
evolution	O
of	O
severe	O
forms	I:C1854779
.	O

The	O
parasite	O
treatment	B:C0087111
also	O
prevented	O
the	O
evolution	O
of	O
severe	O
forms	I:C1854779
.	O

The	O
parasite	O
treatment	O
also	O
prevented	O
the	O
evolution	O
of	O
severe	B:C1854779
forms	I:C1854779
.	O

